lindamycin is a semisynthetic derivative of lincomycin developed in the mid1960’s. Since its introduction, it has become a standard therapy for the treatment of anaerobic infections and is often used to treat Gram positive infections in patients allergic to betalactam antibiotics. More recently, clindamycin has become an important component in the treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections. This issue of Pediatric Pharmacotherapy will provide a basic review of the pharmacology of clindamycin and highlight several new papers describing its use in treating pediatric infections.
Pediatr Pharm. 2008;14(2) © 2008 Children's Medical Center, University of Virginia
Cite this: Use of Clindamycin in Pediatric Infections - Medscape - Apr 17, 2008.